利拉鲁肽联合二甲双胍对2型糖尿病合并冠心病患者的影响  

Effect of Liraglutide combined with Metformin on type 2 diabetes mellitus patients with coronary heart disease

作　　者：梁惠斌 韩毅[2] LIANG Huibin;HAN Yi(Department of Anesthesiology,Shanxi Medical University,Shanxi Province,Taiyuan030000,China;Department of Anesthesiology,the Second Hospital of Shanxi Medical University,Shanxi Province,Taiyuan030001,China)

机构地区：[1]山西医科大学麻醉学院,山西太原030000 [2]山西医科大学第二医院麻醉科,山西太原030001

出　　处：《中国医药导报》2022年第19期98-102,共5页China Medical Herald

基　　金：国家自然科学基金资助项目(81400260);山西省自然科学研究面上项目(20210302123267);山西省卫生健康委科研课题项目(2022020);山西省研究生教育创新计划项目(2021Y433)。

摘　　要：目的观察利拉鲁肽联合二甲双胍对2型糖尿病(T2DM)合并冠心病患者的影响。方法前瞻性分析2021年1月至8月山西医科大学第二医院内分泌科收治的80例2型糖尿病伴冠心病患者的临床资料,按照随机数字表法分为观察组和对照组,每组各40例。观察组在冠心病基本治疗基础上加用利拉鲁肽和二甲双胍,对照组在冠心病基本治疗基础上加用二甲双胍。比较两组治疗前后临床疗效、血糖、血脂、心脏彩超、体重指数(BMI)、内源性孤啡肽(N/OFQ)及脂蛋白相关磷脂酶A2(Lp-PLA2)指标的变化。结果观察组临床疗效优于对照组,差异有统计学意义(P<0.05)。治疗后两组空腹血糖(FPG)、餐后2 h血糖(2hPG)、糖化血红蛋白(HbAlc)、甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(LDL-C)、左室舒张末期内径(LVEDD)、BMI、N/OFQ及Lp-PLA2指标低于治疗前,高密度脂蛋白胆固醇(HDL-C)、左室射血分数(LVEF)、舒张早期最大峰值速度/舒张晚期最大峰值速度(E/A)指标高于治疗前,差异有统计学意义(P<0.05)。治疗后观察组TG、TC、LDL-C、LVEDD、BMI、N/OFQ及Lp-PLA2指标低于对照组,HDL-C、LVEF、E/A指标高于对照组,差异有统计学意义(P<0.05)。结论利拉鲁肽联合二甲双胍能够有效调节血糖、血脂、心功能、BMI、N/OFQ和Lp-PLA2,效果优于单独用二甲双胍,不良反应少。Objective To observe the effect of Liraglutide combined with Metformin on patients with type 2 diabetes mellitus(T2DM)complicated with coronary heart disease.Methods The clinical data of 80 patients with type 2 diabetes mellitus and coronary heart disease admitted to the Department of Endocrinology of the Second Hospital of Shanxi Medical University from January to August 2021 were prospectively analyzed.According to the random number table method,they were divided into observation group and control group,with 40 cases in each group.The observation group was given Liraglutide and Metformin on the basis of the basic treatment of coronary heart disease,while the control group was given Metformin on the basis of the basic treatment of coronary heart disease.The changes in clinical efficacy,blood glucose,blood lipids,cardiac ultrasound,body mass index(BMI),nociceptin/orphanin FQ peptide(N/OFQ),and lipoprotein-associated phospholipase A2(Lp-PLA2)before and after treatment were compared between the two groups.Results The clinical efficacy of the observation group was better than that of the control group,and the difference was statistically significant(P<0.05).After treatment,the fasting plasma glucose(FPG),2 h postprandial blood glucose(2hPG),glycosylated hemoglobin(Hb Alc),triglyceride(TG),total cholesterol(TC),high-density lipoprotein cholesterol(LDL-C),left ventricular end-diastolic diameter(LVEDD),BMI,N/OFQ,and Lp-PLA2 levels were lower than those before treatment,while high density lipoprotein cholesterol(HDL-C),left ventricular ejection fraction(LVEF),maximum peak velocity of early diastolic/maximum peak velocity of late diastolic(E/A)levels of the two groups were higher than those before treatment,and the differences were statistically significant(P<0.05).After treatment,the indexes of TG,TC,LDL-C,LVEDD,BMI,N/OFQ,and Lp-PLA2 in the observation group were lower than those in the control group,while the indexes of HDL-C,LVEF,and E/A were higher than those in the control group,and the differences were statisticall

关 键 词：2型糖尿病 冠心病 利拉鲁肽 二甲双胍 磷脂酶类A2 脂蛋白类 内源性孤啡肽 

分 类 号：R977.15[医药卫生—药品]